Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Drops By 15.3%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant decline in short interest during the month of January. As of January 15th, there was short interest totaling 49,378 shares, a decline of 15.3% from the December 31st total of 58,311 shares. Based on an average daily trading volume, of 15,186 shares, the days-to-cover ratio is currently 3.3 days. Currently, 7.3% of the shares of the company are sold short. Currently, 7.3% of the shares of the company are sold short. Based on an average daily trading volume, of 15,186 shares, the days-to-cover ratio is currently 3.3 days.

ENDRA Life Sciences Price Performance

NDRA traded down $0.05 during mid-day trading on Wednesday, hitting $3.64. The stock had a trading volume of 89,805 shares, compared to its average volume of 26,732. ENDRA Life Sciences has a 1-year low of $2.90 and a 1-year high of $11.96. The stock’s fifty day simple moving average is $4.95 and its 200-day simple moving average is $5.18. The firm has a market capitalization of $2.73 million, a price-to-earnings ratio of -0.14 and a beta of 0.01.

ENDRA Life Sciences (NASDAQ:NDRA) last announced its quarterly earnings results on Friday, November 14th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.95) by $0.20. As a group, research analysts expect that ENDRA Life Sciences will post -47.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NDRA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, January 21st. Ascendiant Capital Markets decreased their price target on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, December 8th. Finally, Wall Street Zen upgraded ENDRA Life Sciences to a “sell” rating in a research note on Saturday, November 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.